(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 17 October 2002 (17.10.2002)

PCT

(10) International Publication Number WO 02/080857 A3

(51) International Patent Classification7: A61K 31/445, C07D 211/22, 211/34

(21) International Application Number: PCT/US02/11251

(22) International Filing Date: 8 April 2002 (08.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/282,521	9 April 2001 (09.04.2001)	US
60/307,752	25 July 2001 (25.07.2001)	US
60/314,396	23 August 2001 (23.08.2001)	US
60/336,930	8 November 2001 (08.11.2001)	US
60/339,041	7 December 2001 (07.12.2001)	US
60/344,114	28 December 2001 (28.12.2001)	US
60/361,780	4 March 2002 (04.03.2002)	US
60/363,482	11 March 2002 (11.03.2002)	US

- (71) Applicant (for all designated States except BB, US): TEVA PHARMACEUTICAL INDUSTRIES LTD. [IL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petah Tiqva (IL).
- (71) Applicant (for BB only): TEVA PHARMACEUTICALS USA, INC. [US/US]; 1090 Horsham Road, P.O. Box 1090, North Wales, PA 19454-1090 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): Ben-Zion [IL/IL]; Lohame HaGhetto 32, Petach Tiqva 49651 (IL). WIZEL, Shlomit [IL/IL]; Yehuda Hanassi 2, Petah Tiqva 49742 (IL). KROCHMAL, Barnaba [IL/IL];

Shevo 503/38, Gilo, 93845 Jerusalem (IL). DILLER, Dov [IL/IL]; Rehov Chida 20, Bayit Vegan, 96464 Jerusalem (IL). GROSS, Irwin [IL/IL]; Idelson 16/24, Rammot gimmel 97665 (IL).

- (74) Agent: BRAINARD, Charles, R.; Kenyon & Kenyon, One Broadway, New York, NY 10004 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (88) Date of publication of the international search report: 18 December 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE

(57) Abstract: The present invention provides novel crystal forms of fexofenadine hydrochloride Forms (V, VI and VIII through XV) and processes for their preparation and preparation of amorphous form and other crystalline forms of fexofenadine hydrochloride. Forms (XIV and XV) are solvates of ethyl acetate, while Form IX is anhydrous, but can be crystallized as solvate of MTBE or cyclohexane. The forms are useful for administration to humans and animals to alleviate symptoms caused by histamine. The present invention further provides pharmaceutical compositions of the new crystalline forms.

INTERNATIONAL SEARCH REPORT

International application No. PCT/US02/11251

IPC(7) :I US CL :! According to B. FIELI Minimum do U.S. : 5 Documentati searched Electronic d CAS-stru	SIFICATION OF SUBJECT MATTER IPC-7 A61K31/445, C07D 211/22, 211/34 514/317, 546/239, 240 of International Patent Classification (IPC) or to both DS SEARCHED Commentation searched (classification system followed 514/317, 546/239, 240 ion searched other than minimum documentation to lata base consulted during the international search (natucture ESTsubclass	by classification symbols) the extent that such documents are in	
C. DOC	UMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where app	Relevant to claim No.	
P, X 	WO 00/71124 A1 (RANBAXY LABORATORIES LID.) 30 November 2000, seep.5-7, examples 1-5. US 5,654,433 A (KING et al.) 05 August 1997, see entire article especially column 19, lines 5-35. WO 93/21156 A1 (DOW PHARMACEUTICALS INC.) 28 October 1993, see entire article especially p.34 lines 24-25, p.34-35 step (e).		6-8, 9-10 1-5, 11-43, 50-93, 113-120 1-43, 50-93, 113-120 1-43, 50-93, 113-120
"A" do to "E" ea "L" do ci su	mailing address of the ISA/US oner of Patents and Trademarks	C. See patent family annex. "T" later document published after the indate and not in conflict with the appear of the principle or theory underlying it document of particular relevance; the considered novel or cannot be considered to involve an inventive stewith one or more other such doon obvious to a person skilled in the arm document member of the same patent Date of mailing of the international society. Authorized officer CELIA CHANG	plication but cited to understand the invention the claimed invention cannot be pred to involve an inventive step the claimed invention cannot be pred the document is combined ments, such combination being t tt family tearch report

INTERNATIONAL SEARCH REPORT

International application No. PCT/US02/11251

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No	
Category	creation of document, with indication, where appropriate, of the relevant passages	Televant to Gain IVe	
Y !	WO 95/31437 A1 (MARION MERREL DOW INC.) 23 November 1995, see enire article especially p. 19-34.	1-120	
A	us 5,925,761 A (SENANAYAKE et al.) 20 July 1999, see entire article.	1-120	